2 Citations (Scopus)


Despite being members of gut microbiota, Enterobacteriaceae are associated with many severe infections such as bloodstream infections. The β-lactam drugs have been the cornerstone of antibiotic therapy for such infections. However, the overuse of these antibiotics has contributed to select β-lactam-resistant Enterobacteriaceae isolates, so that β-lactam resistance is nowadays a major concern worldwide. The production of enzymes that inactivate β-lactams, mainly extended-spectrum β-lactamases and carbapenemases, can confer multidrug resistance patterns that seriously compromise therapeutic options. Further, β-lactam resistance may result in increases in the drug toxicity, mortality, and healthcare costs associated with Enterobacteriaceae infections. Here, we summarize the updated evidence about the molecular mechanisms and epidemiology of β-lactamase-mediated β-lactam resistance in Enterobacteriaceae, and their potential impact on clinical outcomes of β-lactam-resistant Enterobacteriaceae infections.
Original languageEnglish
Pages (from-to)1-22
Number of pages22
JournalInternational Journal of Molecular Sciences
Publication statusPublished - 2020


  • Enterobacteriaceae
  • Molecular resistance
  • β-lactam drugs
  • β-lactamase


Dive into the research topics of 'Molecular mechanisms, epidemiology, and clinical importance of β-lactam resistance in enterobacteriaceae'. Together they form a unique fingerprint.

Cite this